Atocha Romero
occupation: researcher
Articles 55
-
Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial)
-
Incorporating progesterone receptor expression into the PREDICT breast prognostic model
-
Common variants in breast cancer risk loci predispose to distinct tumor subtypes
-
Mendelian randomisation study of smoking exposure in relation to breast cancer risk
-
Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis
-
Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment
-
Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element
-
Transcriptome-wide association study of breast cancer risk by estrogen-receptor status
-
Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes
-
A network analysis to identify mediators of germline-driven differences in breast cancer prognosis
-
Next-generation sequencing for tumor mutation quantification using liquid biopsies
-
Next-generation sequencing to dynamically detect mechanisms of resistance to ALK inhibitors in ALK-positive NSCLC patients: a case report
-
Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses
-
Sex is a strong prognostic factor in stage IV non-small-cell lung cancer patients and should be considered in survival rate estimation
-
Comprehensive cross-platform comparison of methods for non-invasive EGFR mutation testing: Results of the RING observational trial
-
Fine-mapping of 150 breast cancer risk regions identifies 178 high confidence target genes
-
Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes
-
Genome-wide association study of germline variants and breast cancer-specific mortality
-
The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer
-
Cisplatin resistance involves a metabolic reprogramming through ROS and PGC-1α in NSCLC which can be overcome by OXPHOS inhibition
-
Two truncating variants in FANCC and breast cancer risk
-
Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis
-
A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer
-
Cancer-associated fibroblasts modify lung cancer metabolism involving ROS and TGF-β signaling
-
Peritoneal washing is an adequate source for somatic BRCA1/2 mutation testing in ovarian malignancies
-
Tumor burden monitoring using cell-free tumor DNA could be limited by tumor heterogeneity in advanced breast cancer and should be evaluated together with radiographic imaging.
-
Dynamic circulating tumor DNA quantificaton for the individualization of non-small-cell lung cancer patients treatment.
-
Concordance between circulating tumor cells and clinical status during follow-up in anaplastic lymphoma kinase (ALK) non-small-cell lung cancer patients.
-
Association analysis identifies 65 new breast cancer risk loci.
-
Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer.
-
PGC-1alpha levels correlate with survival in patients with stage III NSCLC and may define a new biomarker to metabolism-targeted therapy.
-
Prognostic value of quantitative ctDNA levels in non small cell lung cancer patients.
Human - wd:Q56526307